Pharmacokinetics of adalimumab in inflammatory bowel diseases: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 20, Issue 7, 2014, Pages 1288-1295

  Paul, Stephane ^a   Moreau, Amelie Carla ^a   Del Tedesco, Emilie ^a   Rinaudo, Melanie ^a   Phelip, Jean Marc ^a   Genin, Christian ^a   Peyrin Biroulet, Laurent ^b   Roblin, Xavier ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Adalimumab trough levels; Antibodies to adalimumab; Clinical response; Inflammatory bowel diseases; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; ANTIBODY; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; CROHN DISEASE; DRUG BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADULT; AGE; CHILD; COLITIS, ULCERATIVE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; INFLAMMATORY BOWEL DISEASES; MALE; META ANALYSIS; PHYSIOLOGIC MONITORING; SEVERITY OF ILLNESS INDEX;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MONITORING, PHYSIOLOGIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905496301     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000037     Document Type: Review

References (30)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
3. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.
4. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology. 2014;146:85-95.
5. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.
6. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-358.
7. Lichtenstein GR. Letter from the editor. Gastroenterol Hepatol (N Y). 2013;9:67.
8. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-47; quiz 48.
9. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1-6.
10. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079-1087; quiz e85-e86.
11. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
12. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:80-84.
13. Pradhan RS, Sharma S, Thakkar R. Relationship between adalimumab concentrations and efficacy for the induction of clinical remission in pediatric patients with moderate to severe Crohn's disease. Gastroenterology. 2013;144(Suppl 1):S230.
14. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014;49:100-109.
15. Velayos FS, Sheibani S, Lockton S, et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology. 2013;144(Suppl 1):S91.
16. Mazor Y, Koplov K, Ben Huret D. Evaluating Adalimumab Drug and Antibody Levels as Predictors of Clinical and Laboratory Response in Crohn's Disease Patients.. Vienna, Austria: ECCO; 2013: P517.
17. Dastrich P, Kozeluhova J, Bortlik M, et al. Infliximab but not adalimumab serum trough level is a useful predictor of deep remission in patients with Crohn's disease. Gastroenterology. 2011;140(Suppl 1):S240.
18. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
19. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013;19:1112-1122.
20. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394.
21. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence: study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-415.
22. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
25. Ferrante M, Karmiris K, Compernolle G, et al. Efficacy of ADA in Patients with UC: Restoration of Serum Levels After Dose Escalation Results in a Better Long Outcome.. Stockolm, Sweden: UEGW; 2011: OP312.
26. Sharma S, Pradhan R, Thakkar R. Relationship between adalimumab concentration and efficacy for the maintenance of clinical remission in pediatric patients with moderate to severe Crohn's disease. Gastroentrology. 2013;144(Suppl 1):S231.
27. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122-1126.
28. Bodini G, Savarino V, Fazio V, et al. Relationship between drug serum concentration and clinical activity in patients with CD who achieved remission with adalimumab: a prospective study. Gastroenterology. 2012;142(Suppl 1):S388.
29. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760-767.
30. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106:674-684.